Compare Intuit Inc. (INTU) vs Summit Therapeutics Inc (SMMT) Price & Performance

Intuit (INTU) trades at $303.88, up 2.23% today, with strong technical momentum as it approaches resistance near $307. The company demonstrates robust fundamentals with revenue growth from $18.83B in 2025 to projected $21.4B in 2026, net margins expanding to 21.29%, and consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $379.68 price target, though recent class action lawsuits create near-term sentiment headwinds.

INTU presents a compelling growth story with strong profitability and market leadership in financial software. The primary investment opportunity lies in continued QuickBooks and TurboTax monetization, while risks include legal overhang from securities litigation and competitive pressures in the fintech space. Current valuation at 18.46 P/E appears reasonable given earnings growth trajectory.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.